Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy 

Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy 

Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated disorders

Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide

Sanofi to leverage its next-generation mRNA platform to unlock potential of vaccine-candidate

PARIS and VIENNA – December 1, 2021 – Sanofi announced today it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne. With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline.

The transaction will add ORI-001 to Sanofi’s early-stage pipeline. ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021. In parallel, Sanofi is working to develop additional antigen versions and expects to leverage its next-generation mRNA platform in a comprehensive Ph1/2 trial to start in 2023.  

“The acquisition of Origimm further broadens our vaccines R&D pipeline with a first vaccine candidate against acne, a high medical need for millions of teenagers and adults,” says Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur. “Welcoming Origimm within Sanofi expands our area of expertise by bringing extensive know-how in the field of skin microbiome and skin immunology. We look forward to unlocking the full potential of this candidate”.